A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy.
OBJECTIVE
Octreotide long acting repeatable (LAR) is commonly used to control the symptoms of patients with functional neuroendocrine tumors. Unfortunately, most patients escape control over time and require higher LAR doses or more frequent rescue therapy to remain asymptomatic. Previous work has shown that body weight and monthly LAR dose will significantly affect circulating plasma octreotide levels in patients undergoing therapy.


METHODS
To determine if other parameters change circulating plasma octreotide levels, we prospectively studied 82 patients undergoing long-term LAR therapy.


RESULTS
Multivariate analysis demonstrated that the plasma octreotide levels decrease by approximately 3.4% for each unit of body mass index (BMI) increase (P = 0.03), adjusting for sex and monthly LAR dose. Plasma octreotide levels for females were approximately 47.6% higher than those for males (P = 0.045), adjusting for BMI and monthly LAR dose. Initial and subsequent octreotide LAR doses should take into consideration sex and BMI. Males are estimated to require 14.1-mg (SD, 7.25) higher monthly LAR doses than females with the same BMI.


CONCLUSIONS
We have shown that plasma octreotide levels are affected by not only monthly LAR dose but also BMI and sex. We hope these observations will make choosing initial and subsequent octreotide LAR doses easier for physicians.
Joseph
Saju
S
Sections of Surgical Endocrinology and Hepatobiliary Surgery, Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Li
Gang
G
Lindholm
Erika
E
Zhou
Ying
Y
Go
Vay Liang W
VL
Vinik
Aaron I
AI
O'Dorisio
Thomas M
TM
Mamikunian
Gregg
G
Woltering
Eugene A
EA
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage* / Q000097:blood*; D011446:Prospective Studies; D012737:Sex Factors
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide
J Clin Oncol. 1999 Feb;17(2):600-6
10080605
Pancreas. 2005 Nov;31(4):392-400
16258376
Pancreas. 2008 Jul;37(1):94-100
18580450
Ann Oncol. 2004 Jun;15(6):966-73
15151956
Regul Pept. 1993 Apr 8;44(3):285-95
8097891
Dig Dis Sci. 1995 Jul;40(7):1464-73
7628270